40 patents
Utility
Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Cancer Indications
21 Sep 23
The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer.
Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan J. Dowden, Tom Wickham, Sivan Elloul
Filed: 25 Jan 23
Utility
Methods and compositions for immunomodulation
14 Feb 23
Provided are cells containing exogenous antigen and uses thereof.
Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
Filed: 12 Apr 19
Utility
Methods and compositions for immunomodulation
17 Jan 23
Provided are cells containing exogenous antigen and uses thereof.
Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
Filed: 5 Mar 18
Utility
Therapeutic Cell Systems and Methods for Treating Cancer and Infectious Diseases
24 Mar 22
The present disclosure relates to erythroid cells that have been engineered to include, e.g., at the surface of the cell, one or more exogenous stimulatory polypeptides, wherein the exogenous stimulatory polypeptides presented are sufficient to stimulate an immune killer cell.
Thomas Joseph Wickham, Sivan Elloul
Filed: 27 Sep 21
Utility
Compositions and Methods Related to Multimodal Therapeutic Cell Systems for Autoimmune Indications
10 Mar 22
The invention includes compositions and methods related to multimodal therapies, e.g., for treating immune conditions.
Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham
Filed: 17 Nov 21
Utility
Amplifiable RNAs for Therapeutic Cell Systems
10 Mar 22
This disclosure provides, among other things, amplifiable nucleic acid constructs for expressing a gene of interest in a cell, e.g., an erythroid cell.
Qin Yu, Urjeet Khanwalkar, Omid Harandi, Ewan Dunn, Tanyaporn Pattarabanjird, Avak Kahvejian, Jordi Mata-Fink
Filed: 18 Nov 21
Utility
Therapeutic cell systems and methods for treating cancer and infectious diseases
12 Oct 21
The present disclosure relates to erythroid cells that have been engineered to include, e.g., at the surface of the cell, one or more exogenous stimulatory polypeptides, wherein the exogenous stimulatory polypeptides presented are sufficient to stimulate an immune killer cell.
Thomas Joseph Wickham, Sivan Elloul
Filed: 8 Mar 19
Utility
Functionalized Erythroid Cells
23 Sep 21
Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.
Thomas Wickham, Tiffany Fen-Yi Chen, Xuqing Zhang, Carolyn Sayre, Jordi Mata-Fink, Sivan Elloul, Billy Law, Lenka Hoffman, Kristian Eric Teichert, Shamael Rabia Dastagir
Filed: 27 May 21
Utility
Engineered Erythroid Cells Including HLA-G Polypeptides and Methods of Use Thereof
12 Aug 21
The present disclosure relates to engineered erythroid cells and enucleated cells that include one or more of exogenous HLA-G polypeptides, exogenous immunogenic polypeptides, and exogenous coinhibitory polypeptides wherein the cells are capable of inducing immune tolerance and/or reducing immune response to the exogenous immunogenic polypeptides when administered to a subject.
Regina Sophia Salvat, Christopher Lawrence Moore, Abdulsalam Shaaban
Filed: 1 Jun 20
Utility
Membrane-Receiver Complex Therapeutics
17 Jun 21
Composition comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith.
Jordi Mata-Fink, Avak Kahvejian
Filed: 16 Oct 20
Utility
Functionalized erythroid cells
1 Jun 21
Described herein are novel preparations of functionalized erythroid cells and related compositions, reagents, and methods for use in human pharmaceutical and veterinary applications.
Tom Wickham, Tiffany F. Chen, Xuqing Zhang, Carolyn Sayre, Jordi Mata-Fink, Sivan Elloul, Billy Law, Lenka Hoffman, Kristian Eric Teichert, Shamael Rabia Dastagir
Filed: 16 Feb 18
Utility
Methods of Generating Enucleated Erythroid Cells Using Taurine or Hypotaurine
20 May 21
Provided herein are methods of generating a population of enucleated erythroid cells.
Billy Law, Alan Benjamin Gilbert
Filed: 4 Nov 20
Utility
Methods of Generating Enucleated Erythroid Cells Using Myo-inositol
6 May 21
Provided herein are methods of generating a population of enucleated erythroid cells.
Billy Law, Alan Benjamin Gilbert
Filed: 4 Nov 20
Utility
Methods and compositions for immunomodulation
21 Dec 20
Provided are cells containing exogenous antigen and uses thereof.
Jordi Mata-Fink, John Round, Noubar B. Afeyan, Avak Kahvejian
Filed: 12 Mar 15
Utility
Methods of Generating Enucleated Erythroid Cells
25 Nov 20
Provided herein are methods of generating a population of enucleated erythroid cells.
Jonathan Lipsitz, Brian Joseph Pereira, Bryan Wang, Alan Gilbert
Filed: 21 May 20
Utility
Compositions and Methods Related to Cell Systems for Penetrating Solid Tumors
4 Nov 20
The present disclosure provides, e.g., compositions and method for treating cancers, e.g., solid tumors.
Avak Kahvejian, Robert J. Deans, Jordi Mata-Fink, Sivan Elloul, Nathan Dowden
Filed: 8 Apr 20
Utility
Compositions Including Enucleated Erythroid Cells
28 Oct 20
Provided herein are compositions including enucleated erythroid cells and methods of making and using the same.
Ho Ki Keith Wong, Jie Li
Filed: 23 Apr 20
Utility
Engineered Erythroid Cells Including Loadable Antigen-presenting Polypeptides and Methods of Use
16 Sep 20
The present disclosure provides customizable enucleated erythroid cells or enucleated cells that can be engineered to include, on their surface, a loadable exogenous antigen-presenting polypeptide, wherein the loadable exogenous antigen-presenting polypeptide comprises one or more amino acid substitutions.
Tiffany Fen-Yi Chen, Thomas Joseph Wickham, Christopher Lawrence Moore, Shamael Rabia Dastagir, Douglas Charles Mclaughlin, Regina Sophia Salvat, Alex Richard Nanna
Filed: 19 Feb 20
Utility
Compositions and methods related to multimodal therapeutic cancer indications
20 Jul 20
The invention includes compositions and methods related to multimodal therapies, e.g., for treating a cancer.
Avak Kahvejian, Jordi Mata-Fink, Robert J. Deans, Tiffany F. Chen, John Round, Noubar B. Afeyan, Torben Straight Nissen, Nathan Dowden, Tom Wickham, Sivan Elloul
Filed: 2 Dec 18
Utility
Artificial Antigen Presenting Cells Including Hla-e and Hla-g Molecules and Methods of Use
3 Jun 20
The present disclosure relates to artificial antigen presenting cells (aAPCs), in particular engineered erythroid cells and enucleated cells (e.g., enucleated erythroid cells and platelets), that are engineered to include exogenous-antigen presenting polypeptides comprising either HLA-E or HLA-G polypeptides, which may be used to activate or suppress certain immune cells.
Tiffany Fen-Yi Chen, Thomas Joseph Wickham, Regina Sophia Salvat, Xuqing Zhang
Filed: 2 Dec 19